Oral Procedures in Patients with Glanzmann Thrombasthenia
Author Information
Author(s): Delarue Maxime, Severac François, Soell Martine, Pierre Léa, Desprez Dominique, Bornert Fabien
Primary Institution: University Hospital Strasbourg
Hypothesis
This study evaluates the efficacy and safety of recombinant activated factor VII (rFVIIa) for preventing bleeding during dental procedures in patients with Glanzmann thrombasthenia.
Conclusion
The study supports the efficacy and safety of rFVIIa for preventing bleeding during invasive dental procedures in patients with Glanzmann thrombasthenia.
Supporting Evidence
- 94% of dental procedures were successful with no major bleeding.
- Only minor bleeding complications were observed in 6 out of 102 sessions.
- rFVIIa was administered before dental procedures to prevent bleeding.
Takeaway
Doctors used a special medicine to help patients with a rare bleeding disorder have dental work done without bleeding too much.
Methodology
Data were collected from medical and dental records of patients with Glanzmann thrombasthenia who received rFVIIa for dental procedures.
Potential Biases
Potential biases in patient selection and data collection methods.
Limitations
The study is retrospective and may not account for all variables affecting outcomes.
Participant Demographics
21 patients (10 women, 11 men) aged 8 to 70 years, with a median age of 28.
Statistical Information
P-Value
0.009
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website